Skip to main content

Proligo Inks Deal for RNAx RNAi Technology

NEW YORK, April 26 (GenomeWeb News) - Proligo has signed a deal under which it has gained access to RNAx's RNA interference technology for use in the functional validation of siRNA oligos and gene targets, the companies said today.

 

Proligo owns all information and inventions derived from its work with the RNAx technology.

 

Additional terms of the deal were not disclosed.

 

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.